Clinical Trials Browser

Neoplasm Metastasis

Stomach Neoplasms

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

Osteosarcoma

HER2-mutant Non-Small Cell Lung Cancer

Breast Neoplasms

Unresectable Locally Recurrent Breast Cancer

Brain Neoplasms, Breast Neoplasms

Breast Cancer Metastatic

Salivary Gland Neoplasms

Breast Neoplasms

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

Ovarian Neoplasms, Recurrence

Pancreatic Neoplasms, Colorectal Neoplasms

Gastric Adenocarcinoma

Breast Neoplasms

Advanced Breast Cancer

Breast Neoplasms

Breast Neoplasms

Neoplasm Metastasis

Colorectal Neoplasms

Brain Neoplasms, Glioblastoma, Neoplasm Metastasis, Meningeal Carcinomatosis

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Breast Neoplasms

Colorectal Neoplasms

Neoplasm Metastasis, Neoplasms

Stomach Neoplasms

Breast Neoplasms

HER2-positive Breast Cancer

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Breast Neoplasms, Inflammatory Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Breast Cancer With Brain Metastasis

Breast Neoplasms

Breast Cancer With Brain Metastasis

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Meningeal Carcinomatosis

HER2-low Hormone Receptor Positive Breast Cancer

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Clinical Trials

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

DG-03

Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma

DL-05

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

TUXEDO-4

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

DEMETHER

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

TROY

DPT02

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

TRANSCENDER

PONTIAC

TOP-REAL

HER2CLIMB-04

DPT01

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

HERCULES

Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer

CHIMERA

ELPIS

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

STORM

DESTINY-CRC02

Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers

Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

ANISE

DESTINY-LUNG02

Scalp Cooling in MBC

ADAPTHER2-IV

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

HUDSON

TRADE DXd

TRUDI

ALTER

THUNDER

ARIADNE

THUMB

DESTINY-Breast01

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

DEBBRAH

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

DAISY

DESTINY-Lung01